Rapid Micro Biosystems, Inc. · NASDAQ:RPID
Rapid Micro Biosystems — Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum 2023
18 slides from Rapid Micro Biosystems's conference presentation, Nov 16, 2023
Slide 1: Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum
Rapid Micro Nasdaq: RPID Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum ROB SPIGNESI, PRESIDENT & CEO NOVEMBER 16, 2023
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared by Rapid Micro Biosystems, Inc. (the “Company”) solely for informational purposes. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
Slide 3: Revolutionizing microbial quality control for pharmaceutical manufacturing
We are revolutionizing a critical, regulated part of the global pharmaceutical manufacturing process, bringing microbial quality control into the 21st century 3
Slide 4: Operating behind strong barriers to entry
Operating behind strong barriers to entry First mover advantage, little competition & robust patent portfolio tg An expanding $10B+ market Dominated by manual, legacy processes that face increasing FDA scrutiny Growth Direct® is the industry-leading platform Chosen by two-thirds of the top 20 global
Slide 5: High Volume Testing and Manual Processes
High Volume Testing and monggt by Regulators ~ ih, Subjective and Prone to Human Error pee a JN ~, “ Manual, Paper-based and | Slow > Insecure and Lacking Data Integrity
Slide 6: Introducing a revolution in MQC
Introducing a revolution in MQC SCIENTIFIC AND TECHNOLOGY INNOVATION GROWING DEMAND FOR MORE COMPLEX THERAPIES FASTER & LEANER MANUFACTURING DATA INTEGRITY & SECURITY FOCUS REGULATORY SCRUTINY DISCOVERY & RESEARCH HIGH-THROUGHPUT R&D AUTOMATION Qc & ANALYSIS BIOPROCESSING & MANUFACTURING FLEXIBLE SI
Slide 7: Growth Direct platform bringing Micro QC into the 21st Century
Growth Direct® platform bringing Micro QC into the 215* Century The only fully automated, high-throughput and secure MQC solution... «delivering a compelling value proposition... Data —_ Supports global quality regulatory Integrity if ) compliance and improved data handling and management Proprietar
Slide 8: Growth Direct transforms and modernizes MQC
Growth Direct® transforms and modernizes MQC 2. fy FILL OUT ASSAY INFO 10. & PULL SAMPLES PREPARE SAMPLE & AUTOMATED LOADING 3. 2 = PREPARE SAMPLES i. 4tt PERFORM COUNTS 4. islets} Lop INCUBATOR 12. PERFORM. DUALREAD 2. 5. é PULL SAMPLES 13. & secon eSunts AUTOMATED INCUBATION AND ANALYSIS & DATA HA
Slide 9: | Rapid Micro Biosystems - Confidential
| Rapid Micro Biosystems - Confidential 9
Slide 10: Business model and unit economics driving significant durable growth
Business model and unit economics driving significant durable growth INITIAL PURCHASE AVERAGE ANNUAL ORDER VALUE RECURRING REVENUES! $500 - 600K+ $200 - 250K+ System, LIMS Software & Validation Services High-Yielding Consumables & High-Attach Rate Service Contracts umable usage by a system in routin
Slide 11: The addressable market for MQC testing is large and growing
The addressable market for MQC testing is large and growing ~350M TESTS ANNUALLY + ~10,000 GROWTH DIRECT SYSTEMS GLOBALLY — — Source: HealthAdvances estimates ~$5B Recurring Annual TAM + ~$5B One-time TAM MQC TAM Growth (CAGR 2021 - 2026) Total Market: 8% Biologics (incl. Cell & Gene): 13%+
Slide 12: Automated MQC market is supported by persistent tailwinds
Automated MQC market is supported by persistent tailwinds Increasing regulatory scrutiny Growth in complex biologics, cell, Significant global demand for and enforcement around and gene therapies which require drugs colliding with supply chain disruptions to The number of FDA warning letters due to
Slide 13: • Biologics • Cell & Gene Therapy/ CAR-T • CDMO
• Biologics • Small Molecules • Cell & Gene Therapy/ CAR-T • Personal Care Products • CDMO As of 12/31/22 | Rapid Micro Biosystems 13 * By revenue
Slide 14: | Rapid Micro Biosystems
• • • • • • • • • | Rapid Micro Biosystems 14
Slide 15: Clear path to attractive gross margins
Clear path to attractive gross margins * Investments in manufacturing, supply chain and service a, K infrastructure made to serve top-tier global customer base Reon ACT yeTia = eS ak Improvement Drivers * Business scale not yet covering these costs, impacting Systems Consumables Service current marg
Slide 16: 2023 revenue guidance of at least 30% growth
2023 revenue guidance of at least 30% growth Select Highlights - Q3 2023 Guidance FY 2023! * +30% yearoveryear revenue growth; +17% recurring revenue growth Total Revenue at least $22M (at least 30% growth y/y) * Third quarter in a row exceeding revenue guidance * Placed 5 new Growth Direct systems
Slide 17: Growth Direct is the industry-leading platform
Growth Direct® is the industry-leading platform < S Chosen by two-thirds of the top Operating behind 20 global pharma companies! Enabling advanced . with significant commercial . . strong barriers to entry "9 ume pharmaceutical manufacturing First mover advantage, little ~80% of commercially approve
Slide 18: Thank You
Thank You 4 —_